Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2019

Open Access 01-12-2019 | Influenza Virus | Case report

A severe case of Streptococcal pyogenes empyema following influenza A infection

Authors: Nobuhiro Asai, Hiroyuki Suematsu, Daisuke Sakanashi, Hideo Kato, Mao Hagihara, Hiroki Watanabe, Arufumi Shiota, Yusuke Koizumi, Yuka Yamagishi, Hiroshige Mikamo

Published in: BMC Pulmonary Medicine | Issue 1/2019

Login to get access

Abstract

Background

Any immunological mechanisms induced by influenza virus could cause severe secondary bacterial superinfection such as those by Streptococcus pyogenes [group A streptococcus (GAS)], Streptococcus pneumoniae or Staphylococcus aureus. Over recent years, the frequency of pleural empyema has increased in children with influenza infection.
We present a severe case of acute empyema caused by S.pyogenes after influenza A infection.

Case presentation

A previously healthy 39-year old woman was diagnosed as influenza A and received oral Oseltamivir 75 mg twice daily for 5 days. She had no vaccination of influenza A. Although her influenza A infection improved, she complained of fever and cough to our institute. Chest radiography showed encapsulated pleural effusion of the left lung and pleural effusion which was consistent with acute empyema. Then, she was diagnosed as having acute empyema and was admitted to our institute. Streptococcus pyogenes was identified by pleural fluid culture on day 4. thus, MNZ was changed to clindamycin (CLDM) 600 mg three times a day. While thoracic drainage with intrapleural urokinase and combination antibiotic therapy of ceftriaxone and CLDM were performed, her general condition and chest radiographic findings were not improved. She received video-assisted thoracic debridement on day 10. After the operation, the antibiotic therapy was changed to ABPC 6 g daily iv. Due to good clinical course, the antibiotic therapy was switched to oral amoxicillin 500 mg three times daily on day 28. Then, she was discharged.

Conclusion

Influenza A virus infection could lead to severe GAS infection, while the latter can occur in otherwise healthy individual as well. Physician must consider the possibility of severe GAS infection after influenza A infection.
Literature
1.
go back to reference Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group a streptoccal diseases. Lanset Infect Dis. 2005;5:685–94.CrossRef Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group a streptoccal diseases. Lanset Infect Dis. 2005;5:685–94.CrossRef
2.
go back to reference Aebi C, Ahmed A, Ramilo O. Bacterial complications of primary varicella in children. ClinInfectDis. 1996;23:698–705. Aebi C, Ahmed A, Ramilo O. Bacterial complications of primary varicella in children. ClinInfectDis. 1996;23:698–705.
3.
go back to reference Rush MC, Simon MW. Occurrence of Epstein-Barr virus illness in children diagnosed with group a streptococcal pharyngitis. Clin Pediatr. 2003;42:417–20.CrossRef Rush MC, Simon MW. Occurrence of Epstein-Barr virus illness in children diagnosed with group a streptococcal pharyngitis. Clin Pediatr. 2003;42:417–20.CrossRef
4.
go back to reference Jean C, Louie JK, Glaser CA, Harriman K, Hacker JK, Aranki F, et al. Invasive group a streptococcal infection concurrent with 2009 H1N1 influenza. Clin Infec Dis. 2010;50:e59–62.CrossRef Jean C, Louie JK, Glaser CA, Harriman K, Hacker JK, Aranki F, et al. Invasive group a streptococcal infection concurrent with 2009 H1N1 influenza. Clin Infec Dis. 2010;50:e59–62.CrossRef
5.
go back to reference Ampofo K, Herbener A, Blaschke AJ, Heyrend C, Poritz M, Korgenski K, et al. Association of 2009 pandemic influenza a (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. Pediatr Infect Dis J. 2010;29:905–9.CrossRef Ampofo K, Herbener A, Blaschke AJ, Heyrend C, Poritz M, Korgenski K, et al. Association of 2009 pandemic influenza a (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. Pediatr Infect Dis J. 2010;29:905–9.CrossRef
6.
go back to reference Krenke K, Urbankowska E, Urbankowski T, Lange J, Kulus M. Clinical characteristics of 323 children with parapneumonic pleural effusion and pleural empyema due to community acquired pneumonia. J Infect Chemother. 2016;22:292–7.CrossRef Krenke K, Urbankowska E, Urbankowski T, Lange J, Kulus M. Clinical characteristics of 323 children with parapneumonic pleural effusion and pleural empyema due to community acquired pneumonia. J Infect Chemother. 2016;22:292–7.CrossRef
7.
go back to reference Deceuninck G, Quach C, Panagopoulos M, Thibeault R, Côté-Boileau T, Tapiéro B, et al. Pediatric pleural empyema in the province of Quebec: analysis of a 10-fold increase between 1990 and 2007. J Pediatric Infect Dis Soc. 2014;3:119–26.CrossRef Deceuninck G, Quach C, Panagopoulos M, Thibeault R, Côté-Boileau T, Tapiéro B, et al. Pediatric pleural empyema in the province of Quebec: analysis of a 10-fold increase between 1990 and 2007. J Pediatric Infect Dis Soc. 2014;3:119–26.CrossRef
8.
go back to reference Barthelemy A, Ivanov S, Fontaine J, Soulard D, Bouabe H, Paget C, et al. Influenza a virus-induced release of interleukin-10 inhibits the anti-microbial activities of invariant natural killer T cells during invasive pneumococcal superinfection. Mucosal Immunol. 2017;10:460–9.CrossRef Barthelemy A, Ivanov S, Fontaine J, Soulard D, Bouabe H, Paget C, et al. Influenza a virus-induced release of interleukin-10 inhibits the anti-microbial activities of invariant natural killer T cells during invasive pneumococcal superinfection. Mucosal Immunol. 2017;10:460–9.CrossRef
9.
go back to reference Robinson KM, Choi SM, McHugh KJ, Mandalapu S, Enelow RI, Kolls JK, et al. Influenza a exacerbates Staphylococcus aureus pneumonia by attenuating IL-1β production in mice. J Immunol. 2013;191:5153–9.CrossRef Robinson KM, Choi SM, McHugh KJ, Mandalapu S, Enelow RI, Kolls JK, et al. Influenza a exacerbates Staphylococcus aureus pneumonia by attenuating IL-1β production in mice. J Immunol. 2013;191:5153–9.CrossRef
11.
go back to reference Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol. 2015;34:59–67.CrossRef Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol. 2015;34:59–67.CrossRef
12.
go back to reference Okamoto S, Kawabata S, Fujitaka H, Uehira T, Okuno Y, Hamada S. Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection. Vaccine. 2004;22:2887–93.CrossRef Okamoto S, Kawabata S, Fujitaka H, Uehira T, Okuno Y, Hamada S. Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection. Vaccine. 2004;22:2887–93.CrossRef
13.
go back to reference Chaussee MS, Sandbulte HR, Schuneman MJ, Depaula FP, Addengast LA, Schlenker EH, et al. (2011). In activated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super- infections. Vaccine 2011;29:3773-3781. Chaussee MS, Sandbulte HR, Schuneman MJ, Depaula FP, Addengast LA, Schlenker EH, et al. (2011). In activated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super- infections. Vaccine 2011;29:3773-3781.
14.
go back to reference Patel RA, Binns HJ, Shulman ST. Reduction in pediatric hospitalizations for varicella-related invasive group a streptococcal infections in the varicella vaccine era. J Pediatr. 2004;144:68–74.CrossRef Patel RA, Binns HJ, Shulman ST. Reduction in pediatric hospitalizations for varicella-related invasive group a streptococcal infections in the varicella vaccine era. J Pediatr. 2004;144:68–74.CrossRef
15.
go back to reference Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. CID. 2014;59:358.CrossRef Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. CID. 2014;59:358.CrossRef
16.
go back to reference Stevens DL, Gibbons AE, Bergstrom R, Winn V. The eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:23.CrossRef Stevens DL, Gibbons AE, Bergstrom R, Winn V. The eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:23.CrossRef
17.
go back to reference Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333–40.CrossRef Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333–40.CrossRef
18.
go back to reference Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59:851–7.CrossRef Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59:851–7.CrossRef
19.
go back to reference Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study The Canadian Streptococcal Study Group. Clin Infect Dis. 1999;28:800.CrossRef Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study The Canadian Streptococcal Study Group. Clin Infect Dis. 1999;28:800.CrossRef
20.
go back to reference Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, et al. Plasma from patients with severe invasive group a streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol. 1996;156:3057–64.PubMed Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, et al. Plasma from patients with severe invasive group a streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol. 1996;156:3057–64.PubMed
Metadata
Title
A severe case of Streptococcal pyogenes empyema following influenza A infection
Authors
Nobuhiro Asai
Hiroyuki Suematsu
Daisuke Sakanashi
Hideo Kato
Mao Hagihara
Hiroki Watanabe
Arufumi Shiota
Yusuke Koizumi
Yuka Yamagishi
Hiroshige Mikamo
Publication date
01-12-2019

Other articles of this Issue 1/2019

BMC Pulmonary Medicine 1/2019 Go to the issue